StockData
AC Immune SA logo

AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.13+0.03 (+1.43%)

Close on Nov 19, 2026Market cap $216.71MP/E –Yield –

AC Immune operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AC Immune's operating income for the twelve months ending Dec 31, 2022 was -CHF 70.85M. For fiscal 2025 it was -CHF 69.32M. The highest annual figure on record is CHF 44.54M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 69.32M–
FY2024Dec 31, 2024-CHF 52.38M–
FY2023Dec 31, 2023-CHF 53.62M–
FY2022Dec 31, 2022-CHF 70.85M–
FY2021Dec 31, 2021-CHF 79.01M–
FY2020Dec 31, 2020-CHF 61.26M-237.6%
FY2019Dec 31, 2019CHF 44.54M–
FY2018Dec 31, 2018-CHF 49.55M–
FY2017Dec 31, 2017-CHF 22.54M–
FY2016Dec 31, 2016-CHF 10.46M-156.1%
FY2015Dec 31, 2015CHF 18.62M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-CHF 19.39M–
Q2 FY2024Jun 30, 2024-CHF 20.96M–
Q2 FY2023Jun 30, 2023-CHF 17.05M–
Q4 FY2022Dec 31, 2022-CHF 18.70M–
Q3 FY2022Sep 30, 2022-CHF 13.46M–
Q2 FY2022Jun 30, 2022-CHF 19.86M–
Q4 FY2021Dec 31, 2021-CHF 22.79M–
Q3 FY2021Sep 30, 2021-CHF 20.28M–
Q4 FY2018Dec 31, 2018-CHF 14.49M-554.4%
Q3 FY2018Sep 30, 2018-CHF 12.17M–
Q2 FY2018Jun 30, 2018-CHF 11.57M–
Q1 FY2018Mar 31, 2018-CHF 11.32M–
Q4 FY2017Dec 31, 2017CHF 3.19M–
Q3 FY2017Sep 30, 2017-CHF 9.64M–
Q2 FY2017Jun 30, 2017-CHF 8.25M–
Q1 FY2017Mar 31, 2017-CHF 7.83M–

More AC Immune figures

See a number that looks wrong?